Michel M. Marty

Delayed emesis following anticancer chemotherapy

M. Kris, F. Roila, P. D. De Mulder, 1998, Supportive Care in Cancer.

Combined modality in Hodgkin's disease: Comparison of six versus three courses of MOPP with clinical and surgical restaging

C. Gisselbrecht, M. Boiron, C. Fermé, 1984, Cancer.

Consensus Regarding Multiple-Day and Rescue Antiemetic Therapy

M. Kris, F. Roila, P. Mulder, 1998 .

Consensus regarding multiple day and rescue antiemetic therapy

M. Kris, F. Roila, P. D. De Mulder, 1998, Supportive Care in Cancer.

Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.

M. Marty, J. Extra, R. Bruno, 1993, Cancer research.

Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action

A. Khorana, G. Lyman, M. Mandalà, 2009 .

Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.

S. Culine, M. Marty, I. Madelaine, 1994, Cancer research.

The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot.

D. Lane, M. Marty, T. Soussi, 1992, Cancer research.

Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.

A. Khorana, G. Lyman, M. Mandalà, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fluorouracil (F), adriamycin (A), and cisplatin (P) (FAP): Combination chemotherapy of advanced esophageal carcinoma

C. Gisselbrecht, F. Calvo, D. Belpomme, 1983, Cancer.

Re: Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.

F. Goldwasser, M. Marty, J. Misset, 1998, Journal of the National Cancer Institute.